The Russian Sputnik V vaccine is more than 91% effective, according to the prestigious journal The Lancet

02/02/2021 9:48

• Clarín.com

• Society

Updated 02/02/2021 9:59 AM

The Russian

Sputnik V

vaccine

is 91.6% effective against the coronavirus in its symptomatic manifestations, according to an analysis of clinical trials published Tuesday by

The Lancet

medical journal

and validated by independent experts.

Preliminary results consider that the vaccine, administered in two doses, "showed great efficacy" and was well tolerated by volunteers over 18 years of age who participated in the last stage of clinical trials.

This was indicated by Inna Dolzhikova, a researcher at the Gamaleya National Center of Russia and co-author of the study.

Meanwhile, the efficacy in the group aged over 60 years was 91.8% and did not differ statistically from the group aged 18 to 60 years.

In the interim analysis of the phase III clinical trial, the specialists also evaluated the adverse effects and concluded that most of them (94%) were mild and manifested with flu-like symptoms, injection site reactions, headache and asthenia.

The key fact is that there were no serious adverse events associated with vaccination, as confirmed by the Independent Data Monitoring Committee.

The Sputnik V vaccine has already been registered in 16 countries, including Argentina, which began the vaccination campaign in the last days of 2020 and is progressing with delays in health workers.

This immunization was also recorded in Russia, the Republic of Belarus, Serbia, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the United Arab Emirates, Iran, the Republic of Guinea, Tunisia and Armenia.

News in development

With information from AFP